TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3776447
Drug: Thiopental 5
Normalized name: thiopental 5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiopental 5 mg/kg followed by suxamethonium 1.5 mg/kg i.v.
Study: 3776447
Drug: Enflurane with
Normalized name: Enflurane
DrugBank: Enflurane (DB00228)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enflurane with suxamethonium 2 mg/kg
Study: 30929823
Drug: Nintedanib 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nintedanib 200 mg/day until disease progression or unacceptable toxicity
Study: 30929823
Drug: Nintedanib 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nintedanib 200 mg/day
Study: 27841945
Drug: Greater expression
Normalized name: greater celandine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Greater expression of intestinal cholesterol metabolism genes (NPC1L1, ABC‐G5, ABC‐G8, ABC‐A1, MTTP, SREBP‐2)
Study: 26002728
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg resveratrol for 6 weeks
Study: 21274547
Drug: Oral intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral intake of a venotonic drug (micronized purified flavonoid fraction, Daflon 1,000 mg × 3) for 20 days
Study: 21274547
Drug: Standard conservative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard conservative treatment alone
Study: 19846544
Drug: Dietary intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dietary intervention plus n-3 fatty acid supplementation (6 g/d)
Study: 16895071
Drug: Risedronate, 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risedronate, 2.5 mg/day, daily
Study: 16895071
Drug: Placebo, daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, daily
Study: 9602595
Drug: 0.9% sodium
Normalized name: LMD with 0.9% Sodium Chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% sodium chloride (saline) 50 ml
Study: 9602595
Drug: 20 ml
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 ml of 0.5% bupivacaine solution with epinephrine 1:200,000 diluted with saline to a final volume of 50 ml
Study: 9602595
Drug: 20 ml
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 ml of 2% lidocaine with epinephrine 1:200,000 diluted with saline to a final volume of 50 ml
Study: 8022633
Drug: NASCIS dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: NASCIS dose of methylprednisolone
Study: 3046231
Drug: Ibuprofen (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (400 mg, 4 times a day)
Study: 3046231
Drug: Aspirin (650
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (650 mg, 4 times a day)
Study: 23704713
Drug: Vildagliptin (DPP4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vildagliptin (DPP4 inhibitor) during OGTT
Study: 23704713
Drug: Isoglycaemic i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoglycaemic i.v. glucose infusion (IIGI)
Study: 19138452
Drug: Hyperbaric oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric oxygen therapy in addition to standard medical therapy (prednisolone starting at 1 mg/kg)
Study: 19138452
Drug: Standard medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard medical therapy (prednisolone starting at 1 mg/kg)
Study: 16523808
Drug: Radiotherapy dose
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radiotherapy dose of 60 Gy in 30 fractions
Study: 16523808
Drug: Radiotherapy dose
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radiotherapy dose of 74 Gy at 2 Gy/fraction
Study: 16523808
Drug: Surviving fraction
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surviving fraction of tumour cells after a radiation dose of 2 Gy (SF2)
Study: 11522564
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg elemental Zinc daily for 5 months
Study: 29113874
Drug: d-fenfluramine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: d-fenfluramine (30 mg, p.o.)
Study: 2906887
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg terfenadine-120 mg pseudoephedrine hydrochloride combination
Study: 2906887
Drug: 120 mg
Normalized name: papain 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg pseudoephedrine hydrochloride (extended release)
Study: 28668627
Drug: 3.0g vigabatrin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.0g vigabatrin solution
Study: 28668627
Drug: 6.0g vigabatrin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6.0g vigabatrin solution
Study: 28668627
Drug: Placebo vigabatrin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo vigabatrin solution
Study: 25904205
Drug: PPNa-DBS combined
Normalized name: DB-OTO
DrugBank: DB-OTO (DB18278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PPNa-DBS combined with levodopa treatment
Study: 23556334
Drug: Posaconazole suspension
Normalized name: Posaconazole
DrugBank: Posaconazole (DB01263)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Posaconazole suspension administered orally in the fasted state
Study: 23556334
Drug: Posaconazole suspension
Normalized name: Posaconazole
DrugBank: Posaconazole (DB01263)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Posaconazole suspension administered orally with a high-fat meal
Study: 2423652
Drug: CVPP, ABOS,
Approvals — FDA: no, EMA: no, PMDA: no
Description: CVPP, ABOS, CVPP/ABOS (all treatments)
Study: 2423652
Drug: Complete responders
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complete responders (all treatments)
Study: 20400651
Drug: Itraconazole 100
Normalized name: itraconazole 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itraconazole 100 mg (first dose 200 mg) twice daily for 5 days
Study: 15260882
Drug: 100 mcg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mcg/day vitamin D
Study: 15260882
Drug: 15 mcg/day
Normalized name: estradiol 45 MCG / levonorgestrel 15 MCG/Day Weekly Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mcg/day vitamin D
Study: 15260882
Drug: Both doses
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both doses of vitamin D
Study: 11429371
Drug: Topical Anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Anesthesia
Study: 11429371
Drug: Cuff Volume
Normalized name: VOLUME EXPANDERS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cuff Volume (10 mL or 30 mL)
Study: 11429371
Drug: LMA vs
Normalized name: VS-4718
DrugBank: VS-4718 (DB15273)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LMA vs PLMA at 30 mL cuff volume
Study: 8249871
Drug: Gradually increasing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gradually increasing amounts of lactose in milk until maximum lactose dose tolerated was determined.
Study: 8249871
Drug: Breath-hydrogen tests
Normalized name: Hydrogen
DrugBank: Hydrogen (DB15127)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Breath-hydrogen tests with the maximum dose of lactose tolerated.
Study: 3436031
Drug: Oral mixed
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral mixed grass‐maize pollen extract
Study: 28650526
Drug: Formulation A
Normalized name: meningococcal vaccine of unknown formulation and unknown serogroups
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulation A (30 mg)
Study: 28650526
Drug: Formulation B
Normalized name: Hep B, unspecified formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulation B (30 mg)
Study: 28650526
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation (30 mg)
Study: 19624856
Drug: NOP‐47 (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: NOP‐47 (5 g/day for 2 weeks)
Study: 1380588
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of nifedipine (20 mg b.i.d.) and doxazosin (2 mg o.d.)
Study: 8491245
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of nifedipine and doxazosin
Study: 3904643
Drug: Prostaglandin E1
Normalized name: Prostaglandin E1
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prostaglandin E1 (PGE1) administered intravenously at 10 ng/kg/min for 72 hours
Study: 3904643
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered intravenously for 72 hours
Study: 30949987
Drug: Pentoxifylline (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentoxifylline (400 mg twice a day)
Study: 29528914
Drug: Cell culture-derived
Normalized name: casein, emmental cultured
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cell culture-derived subunit trivalent inactivated influenza vaccine (NBP607)
Study: 29528914
Drug: Egg-based control
Normalized name: EGG
DrugBank: Egg (DB10529)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Egg-based control vaccine
Study: 15950492
Drug: Paroxetine 20
Normalized name: PARoxetine 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine 20 mg daily for 30 days
Study: 11920396
Drug: Anakinra 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anakinra 1.0 mg/kg + MTX
Study: 11920396
Drug: Anakinra 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anakinra 2.0 mg/kg + MTX
Study: 11920396
Drug: Anakinra (0.04,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anakinra (0.04, 0.1, 0.4 mg/kg) + MTX
Study: 10796060
Drug: Terbutaline delivered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbutaline delivered from a pressurized metered dose inhaler (pMDI) at 22 degrees C
Study: 10796060
Drug: Terbutaline delivered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbutaline delivered from a pressurized metered dose inhaler (pMDI) at -10 degrees C
Study: 10796060
Drug: Terbutaline delivered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbutaline delivered from a pressurized metered dose inhaler (pMDI) at -10 degrees C after 2000 microg
Study: 8697553
Drug: Neostigmine (dose-dependent)
DrugBank: Neostigmine (DB01400)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Neostigmine (dose-dependent)
Study: 1317272
Drug: Atropine (1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine (1.2 mg)
Study: 6734078
Drug: Biliary excretion
Normalized name: gonorrheal urethral secretion human
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biliary excretion of radioactive labelled sulphated bile acids
Study: 31298357
Drug: Professional oral
Normalized name: Dentek Professional Oral Care Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Professional oral hygiene session
Study: 29496516
Drug: DHEA+estrogen/progestin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHEA+estrogen/progestin therapy
Study: 25872641
Drug: Participant-customised nutrition
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participant-customised nutrition education programme (8 weekly sessions of 2-2.5 hours)
Study: 20718773
Drug: NNC126‐0083 (0·02,
Approvals — FDA: no, EMA: no, PMDA: no
Description: NNC126‐0083 (0·02, 0·04, 0·08 and 0·16 mg protein/kg)
Study: 17504357
Drug: Sodium picosulphate
Normalized name: Sodium Picosulfate
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium picosulphate (7 mg for three consecutive nights)
Study: 15258718
Drug: venlafaxine ER
Normalized name: Venlafaxine ER
Approvals — FDA: no, EMA: no, PMDA: no
Description: venlafaxine ER fixed low dose (75 mg/day)
Study: 15258718
Drug: venlafaxine ER
Normalized name: Venlafaxine ER
Approvals — FDA: no, EMA: no, PMDA: no
Description: venlafaxine ER flexible higher dose (150-225 mg/day)
Study: 15258718
Drug: venlafaxine ER
Normalized name: Venlafaxine ER
Approvals — FDA: no, EMA: no, PMDA: no
Description: venlafaxine ER (at any dose)
Study: 10910491
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg meperidine
Study: 9261669
Drug: High-dose pyridoxine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose pyridoxine and magnesium (HDPM) at an average dose of 638.9 mg of pyridoxine and 216.3 mg of magnesium oxide
Study: 8275623
Drug: Oral physostigmine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral physostigmine salicylate
Study: 3325468
Drug: IFN‐beta‐containing cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN‐beta‐containing cream
Study: 25468685
Drug: Sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham treatment (candy corn)
Study: 25880068
Drug: Indapamide sustained
Normalized name: Indapamide
DrugBank: Indapamide (DB00808)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indapamide sustained release 1.5 mg ± perindopril 2 to 4 mg
Study: 16239059
Drug: Gingicain Spray
Normalized name: Gingicaine
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gingicain Spray
Study: 16239059
Drug: Gingicaine Topical
Normalized name: Gingicaine
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gingicaine Topical Anesthetic
Study: 11139801
Drug: Oral glycoprotein
Normalized name: Zaire ebolavirus envelope glycoprotein Injection [Ervebo]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral glycoprotein IIb/IIIa antagonists
Study: 3944837
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment with daily hydrotherapy and twice daily applications of topical antimicrobial agents until granulating beds could receive autografts
Study: 22364823
Drug: Labetalol 0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Labetalol 0.4 mg/kg IV (prevention)
Study: 22364823
Drug: Nicardipine 20
Normalized name: nicardipine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicardipine 20 μg/kg IV (prevention)
Study: 22364823
Drug: Labetalol 0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Labetalol 0.4 mg/kg IV (treatment)
Study: 22364823
Drug: Nicardipine 20
Normalized name: nicardipine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicardipine 20 μg/kg IV (treatment)
Study: 20843249
Drug: Darbepoetin alfa
Normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Darbepoetin alfa (initial doses based on weight)
Study: 20843249
Drug: Darbepoetin alfa
Normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Darbepoetin alfa (higher doses)
Study: 12525526
Drug: Chemotherapy arm
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chemotherapy arm (cisplatin and fluorouracil followed by surgery)
Study: 10967380
Drug: Aggressive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aggressive treatment combining polypectomy, intra‐maxillary intubation through the inferior meatus, macrolide administration
Study: 8317002
Drug: Electronic rectal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electronic rectal temperature measurement with Ivac thermometer
Study: 8317002
Drug: Electronic rectal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electronic rectal temperature measurement with Ivac thermometer after calibration
Study: 3545909
Drug: Methylprednisolone (96
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone (96 mg in three divided doses for 7 days followed by a 2-day tapering)
Study: 25591391
Drug: Sulphadoxine‐pyrimethamine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulphadoxine‐pyrimethamine plus azithromycin (SPAZ) monthly from second trimester
Study: 23429964
Drug: Inhaled dry
Normalized name: Dry Powder Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled dry powder mannitol 320 mg bid for 12 weeks
Study: 23429964
Drug: Inhaled dry
Normalized name: Dry Powder Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled dry powder mannitol 320 mg bid for 12 weeks (subgroup study)
Study: 18811806
Drug: Primary implants
Normalized name: Sodium primary phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primary implants for LBBB
Study: 12911281
Drug: New AChR
Approvals — FDA: no, EMA: no, PMDA: no
Description: New AChR antibody test using a mixture of AChR from TE671‐ε and TE671‐γ cells
Study: 9121823
Drug: Consumption of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Consumption of analgesics (opioids and NSAIDs)
Study: 1848392
Drug: Lisinopril (equal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril (equal milligram dosage)
Study: 1848392
Drug: Enalapril (constant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (constant dosage)
Study: 1848392
Drug: Lisinopril (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril (5 mg tablet per day)
Study: 1848392
Drug: Lisinopril (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril (10 mg tablet per day)
Study: 1848392
Drug: Lisinopril (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril (20 mg tablet per day)
Study: 6653136
Drug: Conventional capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional capsules (600 mg disopyramide in 3 divided doses)
Study: 6653136
Drug: Conventional capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional capsules (500 mg disopyramide daily for 11 days)
Study: 6653136
Drug: Sustained-release tablets
Normalized name: Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release tablets (500 mg disopyramide daily for 11 days)
Study: 6653136
Drug: Sustained-release tablets
Normalized name: Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release tablets (500 mg disopyramide daily for 30 days)
Study: 6653136
Drug: Disopyramide treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disopyramide treatment
Study: 6653136
Drug: Disopyramide sustained-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disopyramide sustained-release tablets
Study: 30517586
Drug: Guided imagery
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guided imagery relaxation therapy
Study: 24419112
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy plus hypnosis (CBTH)
Study: 22442025
Drug: IPC treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: IPC treatment
Study: 20465893
Drug: Ozone therapy
Normalized name: ozone
DrugBank: Ozone (DB12510)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ozone therapy for one week
Study: 20465893
Drug: Ozone therapy
Normalized name: ozone
DrugBank: Ozone (DB12510)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ozone therapy for two weeks
Study: 20465893
Drug: Ozone therapy
Normalized name: ozone
DrugBank: Ozone (DB12510)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ozone therapy for four weeks
Study: 17468821
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg ropivacaine
Study: 17468821
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg ropivacaine
Study: 14699453
Drug: Miltefosine (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Miltefosine (2.5 mg/kg per day for 28 days)
Study: 8792486
Drug: Norfloxacin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norfloxacin (400 mg) twice daily for 10 days
Study: 8792486
Drug: Placebo tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets twice daily for 10 days
Study: 29290547
Drug: Condition 2
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Condition 2 (room without acoustic treatment with noise reproduction)
Study: 29290547
Drug: Condition 1
Normalized name: zinc pyrithione
DrugBank: Pyrithione (DB06815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Condition 1 (room without acoustic treatment and without noise reproduction)
Study: 29020983
Drug: AZD5069 (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD5069 (40 mg) administered orally twice daily for 24 weeks
Study: 26501236
Drug: Systemic corticosteroid
Normalized name: CORTICOSTEROIDS FOR SYSTEMIC USE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic corticosteroid therapy
Study: 16968726
Drug: Subcutaneous epoetin-alpha
Normalized name: Epoetin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous epoetin-alpha (SC-EPO; EPREX; 1000 U twice weekly)
Study: 16968726
Drug: Subcutaneous epoetin-alpha
Normalized name: Epoetin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous epoetin-alpha (SC-EPO; 2000 U three times weekly)
Study: 16287442
Drug: 5 mL
Normalized name: WATER,INHL 5 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mL lidocaine‐prilocaine cream
Study: 11888953
Drug: Montelukast, 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast, 10 mg, once daily for 4 weeks
Study: 11888953
Drug: Placebo tablet,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet, once daily for 4 weeks
Study: 7825527
Drug: 8 g
Normalized name: Theranost 68 Ga Rgd
DrugBank: NODAGA-THERANOST Ga-68 (DB16940)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 g fine coffee grounds per day for 3 weeks
Study: 31988276
Drug: Preoperative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative treatment and surgical resection (multimodal treatment).
Study: 31236679
Drug: Uncomplicated acute
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uncomplicated acute appendicitis (surgical treatment arm of the APPAC trial)
Study: 28464867
Drug: Behaviour change
Normalized name: monofluorophosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behaviour change communication (BCC) on maternal nutrition during pregnancy, exclusive breastfeeding, and complementary feeding, along with prenatal nutritional supplement (PNS) and complementary food supplement (CFS)
Study: 23218022
Drug: Cognitive therapy
Normalized name: cognitive therapy software
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive therapy plus low-dose risperidone
Study: 23218022
Drug: Cognitive therapy
Normalized name: cognitive therapy software
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive therapy plus placebo
Study: 23218022
Drug: Supportive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive therapy plus placebo
Study: 11697643
Drug: Combination therapies
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapies involving vaccines
Study: 9549738
Drug: Bupivacaine 0.25%
Normalized name: BUPIVACAINE 0.25%/NS INJ 400ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 0.25% 2 mg.kg‐1
Study: 9549738
Drug: Ropivacaine 0.2%
Normalized name: ROPivacaine 0.2% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 0.2% 2 mg.kg‐1